Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 12, 2007, Pages 4598-4601

  Neggers, Sebastian J C M M ^a   Van Aken, Maarten O ^a   Janssen, Joop A M J L ^a   Feelders, Richard A ^a   De Herder, Wouter W ^a   Van Der Lely, Aart Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; LIVER ENZYME; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GALLSTONE; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS ADENOMA; MALE; MONOTHERAPY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TUMOR VOLUME;

EID: 36849041110     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1234     Document Type: Article

References (24)

1. Swearingen B, Barker 2nd FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
2. Barkan AL 2003 Radiotherapy in acromegaly: the argument against. Clin Endocrinol (Oxf) 58:132-135
3. Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici RM 2005 The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 62:210-216
4. Roberts BK, Ouyang DL, Lad SP, Chang SD, Harsh GRt, Adler Jr JR, Soltys SG, Gibbs IC, Katznelson L. 2007 Efficacy and safety of CyberKnife radiosurgery for acromegaly. Pituitary 10:19-25
5. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F 2005 Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90:2731-2739.
6. Sheppard MC 2003 Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 58:387-399
7. Ayuk J, Stewart SE, Stewart PM, Sheppard MC, European Sandostatin LARG 2004 Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf) 60:375-381
8. Jallad RS, Musolino NR, Salgado LR, Bronstein MD 2005 Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 63:168-175
9. Bronstein MD 2006 Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res 35:129-134
10. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM 2003 Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090-3098
11. Gilbert J, Ketchen M, Kane P, Mason T, Baister E, Monaghan M, Barr S, Harris PE 2003 The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary 6:11-18
12. Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ 2002 Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol (Oxf) 56:303-311
13. Koop BL, Harris AG, Ezzat S 1994 Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 130:581-586
14. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
15. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
16. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R 2006 Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91:85-92
17. Trainer PJ, Drake WM, Perry LA, Taylor NF, Besser GM, Monson JP 2001 Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J Clin Endocrinol Metab 86:2989-2992
18. Lindberg-Larsen R, Moller N, Schmitz O, Nielsen S, Andersen M, Orskov H, Jorgensen JO 2007 The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724-1728
19. van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW 2001 Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 86:478-481
20. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ 2005 Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644-1646
21. Elmlinger MW, Kuhnel W, Weber MM, Ranke MB 2004 Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 42:654-664
22. Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ 2006 Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol 154:805-806
23. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A 2005 Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152:61-66
24. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H, Strasburger CJ 2006 Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 154:213-220